Hims & Hers Health, Inc. (HIMS)

Market Closed

10 Aug, 20:00

NYSE

31. 77

+0.18

+0.5698%

Pre Market

29. 73

-2.04 -6.4212%

7.05B Market Cap

- P/E Ratio

- Div Yield

16.1M Volume

-0.14 Eps

$ 31.59

Previous Close

Investors:

+97

Analysts:

Add Transaction

Day Range

30.9 31.86

Year Range

13.74 65.3

Want to track HIMS and more in your Portfolio? 🎯

Get Started For Free

Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Seekingalpha | 5 months ago

HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO

Forward-looking guidance initially plagued Hims & Hers (HIMS) shares, says Christine Short, though she believes leadership did a good job at "refocusing" goals. She points to the company's businesses beyond GLP-1s showing signs of promise.

Youtube | 5 months ago

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 5 months ago

HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.

Zacks | 5 months ago

Hims & Hers Health: Don't Get Lost In The Weeds

Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027.

Seekingalpha | 5 months ago

Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading

Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $617.8M (+28% YoY) and adjusted EBITDA of $66.3M, but subscriber growth and Q1 guidance disappointed due to GLP-1 headwinds. International expansion and labs initiatives are key growth drivers, with management targeting $1B+ annual international revenue and $1.3B adjusted EBITDA by 2030.

Seekingalpha | 5 months ago